IN8bio, Inc. (INAB)
| Market Cap | 9.46M -2.6% |
| Revenue (ttm) | n/a |
| Net Income | -18.67M |
| EPS | -1.48 |
| Shares Out | 9.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,198 |
| Open | 0.9500 |
| Previous Close | 0.9655 |
| Day's Range | 0.9306 - 0.9908 |
| 52-Week Range | 0.8700 - 2.7300 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+629.17%) |
| Est. Earnings | Nov 9, 2026 |
About INAB
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 629.17% from the latest price.
News
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell e...
IN8bio Transcript: Small-Cap Virtual Conference
The presentation highlighted INB-619’s in vitro B-cell depletion and low IL-6 signal, with animal data expected this fall. Glioblastoma data showed improved median PFS and OS; FDA guidance on a potential registrational path is expected this year.
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for can...
IN8bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Gamma delta T cell therapies and engagers show promising efficacy and safety in glioblastoma and autoimmune indications, with no major toxicities and strong preclinical results. Regulatory discussions and new data are expected this year, while strategic partnerships and leadership hires support growth.
IN8bio Slides: Corporate presentation
IN8bio has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for can...
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they ad...
IN8bio reports Q2 EPS (25c), consensus (37c)
“The second quarter marked an important period of scientific and clinical validation for gammadelta T cell therapeutics and IN8bio (INAB). Our gammadelta TCE platform is progressing, with INB-619 adva...
IN8bio Quarterly report: Q2 2026
IN8bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
IN8bio Earnings release: Q2 2026
IN8bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
IN8bio therapy doubles progression free survival in brain cancer trial
IN8bio (INAB) announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology. “These peer-reviewed results validate the scientific found...
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieve...
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) f...
IN8bio Slides: Corporate presentation
IN8bio has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
IN8bio announces updated INB-200, INB-400 study data
IN8bio (INAB) announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting. Among patients…
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Re...
IN8bio Transcript: R&D Day 2026
The company is advancing a pan-gamma-delta T cell engager for autoimmune and oncology indications and a drug-resistant immunotherapy for glioblastoma, both showing promising efficacy and safety. Repeat dosing and deep immune profiling differentiate their approach, with strong financials supporting progress toward pivotal trials and regulatory engagement in 2024.
IN8bio Slides: FY 2026
IN8bio has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 21, 2026.
IN8bio Registration statement: Registration filing
IN8bio filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-ca...
IN8bio Quarterly report: Q1 2026
IN8bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
IN8bio Earnings release: Q1 2026
IN8bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies...
IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
Gamma delta T cell therapies showed promising clinical results in glioblastoma and leukemia, with no major toxicities and statistically significant survival benefits. The proprietary T-cell engager platform targets autoimmune diseases with reduced toxicity, and key clinical and preclinical milestones are expected later this year.
IN8bio Proxy statement: Proxy filing
IN8bio filed a proxy statement on March 26, 2026, providing details for shareholder voting and corporate governance matters.